U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07905599) titled 'Molecular Evidence of Rejection Intervention Trial' on Oct. 21.
Brief Summary: MERIT is a double-blind, multi-center, placebo-controlled, randomized clinical trial. Heart transplant recipients with dual-positive GEP/dd-cfDNA assays with a corresponding negative biopsy between 2 months and 2 years post-transplant will be randomized to treatment with either high-dose oral steroids or placebo, in addition to standard of care therapy.
Study Start Date: March, 2027
Study Type: INTERVENTIONAL
Condition:
Heart Transplant Rejection
Intervention:
DRUG: Prednisone
100mg per day for three days following randomization
DRUG: Placebo
Mat...